MapLight Therapeutics (MPLT) grants RSUs and options to CMO

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics Chief Medical Officer Erin Pennock Foff reported new equity awards in the company’s voting common stock. She received 13,360 restricted stock units at a price of $0, which begin vesting on January 1, 2027 and then quarterly in equal installments, subject to continued service.

She was also granted an employee stock option for 54,240 shares at an exercise price of $15.7 per share. One quarter of these option shares vest on February 5, 2027, with the remainder vesting monthly thereafter, again contingent on ongoing service. Following these grants, she directly beneficially owns 403,835 shares of voting common stock and 54,240 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Foff Erin Pennock

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	54,240	$0.00	--
Grant/Award	Voting Common Stock	13,360	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 54,240 shares (Direct); Voting Common Stock — 403,835 shares (Direct)

Footnotes (1)

Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/09/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foff Erin Pennock

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	02/05/2026		A		13,360⁽¹⁾	A	$0⁽²⁾	403,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		54,240		⁽³⁾	02/04/2036	Voting Common Stock	54,240	$0	54,240	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MapLight Therapeutics (MPLT) report for its CMO?

MapLight Therapeutics reported that Chief Medical Officer Erin Pennock Foff received new stock-based awards. She was granted 13,360 restricted stock units at $0 and an employee stock option for 54,240 shares at $15.7, both vesting over time with continued service.

How many RSUs did the MapLight Therapeutics (MPLT) CMO receive and how do they vest?

Erin Pennock Foff received 13,360 restricted stock units. One quarter vests on January 1, 2027, and one sixteenth vests on each April 1, July 1, October 1, and January 1 thereafter, as long as she continues serving the company through each vesting date.

What are the terms of the employee stock option granted to the MPLT CMO?

The CMO received an employee stock option covering 54,240 shares of voting common stock at a $15.7 exercise price. One quarter of the option vests on February 5, 2027, with the remaining shares vesting monthly thereafter, contingent on continued service on each vesting date.

How many MapLight Therapeutics shares does the CMO own after these transactions?

After the reported grants, Erin Pennock Foff directly beneficially owns 403,835 shares of MapLight Therapeutics voting common stock. She also holds an employee stock option for 54,240 underlying shares, which will vest over time according to the schedule described in the Form 4 footnotes.

Are the new MapLight Therapeutics RSUs settled in voting common stock?

Each restricted stock unit granted to the CMO represents a contingent right to receive one share of MapLight Therapeutics voting common stock. Actual receipt depends on meeting the vesting schedule while she continues serving the company on each specified vesting date.